Model No. | Nomenclature | Genotype |
---|---|---|
8907-F | B6NTac.C-Tg(HLA-A*1101/H2-Kb)A11.01 | tg/wt |
8907-M | B6NTac.C-Tg(HLA-A*1101/H2-Kb)A11.01 | tg/wt |
Model No. | Nomenclature | Genotype |
---|---|---|
8907-F | B6NTac.C-Tg(HLA-A*1101/H2-Kb)A11.01 | tg/wt |
8907-M | B6NTac.C-Tg(HLA-A*1101/H2-Kb)A11.01 | tg/wt |
Nomenclature: B6NTac.C-Tg(HLA-A*1101/H2-Kb)A11.01
Origin
The HLA-A11 model was generated by Pharmexa-Epimmune. The model was created by microinjecting a chimeric transgene combining a fragment of the cDNA clone of the human HLA-A*1101 gene that included leader sequence, α1 and α2 domains ligated to a fragment of the murine H2-Kb gene containing the α3, transmembrane and cytoplasmic domains. This transgene was microinjected into CxB6 zygotes. The resultant mice from Founder Line A11.01 were backcrossed six generations to C57BL/6J. Taconic received stock from Pharmexa-Epimmune in 2008. The line was embryo transfer derived, backcrossed to C57BL/6NTac for a total of 11 generationsand then intracrossed to homozygosity. In the production colony, wild type C57BL/6NTac animals are bred to homozygous males to produce hemizygous pups on the C57BL/6NTac background. In addition, another production colony is breeding BALB/cAnNTac females with homozygous males on the C57BL/6NTac background to produce hemizygous CB6F1 pups, which are sold under model #9660.
Initial Publication:
Alexander J, Oseroff C, Sidney J, Wentworth P, Keogh E, Hermanson G, Chisari FV, Kubo RT, Grey HM, Sette A. (1997) Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J Immunol 159(10):4753-61. Erratum in: J Immunol 1999 162(5):3104.
Need more info? Click the live chat button or Contact Us
Packing Practices
Taconic standard practice is to recombine animals of different home cages and/or ages from a single model and sex during packing, except in specific cases where Taconic's animal welfare policy prohibits recombination due to aggression or other concerns. When an order is fulfilled with animals from more than one week of birth, this standard practice results in animals from a range of birth weeks packed together in a single TTC. When an order is fulfilled with animals from genotyped models, this standard practice results in animals from different home cages packed together in a single TTC.
Customers who wish to keep animals from different weeks of birth separated should place orders with the special instruction "Divide and label by age." Note that this special request can result in increased costs for additional Taconic Transit Cages, dividers and/or freight charges.
Taconic discourages other types of custom packing requests as they can have a negative impact on animal welfare. Learn more.
HLA expression on spleen cells in HLA-A11 mice on two genetic backgrounds
Figure 1: Expression of HLA-A11 in model #s 8907 and 9660 was measured on spleen cells by flow cytometry using a pan-HLA-ABC antibody. Significant expression of HLA-A11 is seen in both models compared to a wild type C57BL/6 control. Expression levels are somewhat lower in hemizygous mice of model #9660 (on a CB6F1 background) compared to homozygous or hemizygous mice of model #8907 (on a C57BL/6 background), but are sufficient for experimental performance as detailed in many published references. Specific functional relevance of expression differences between models is unclear, and the choice of model for a particular experiment should include not just expression levels but also the role of Th1 vs Th2 immune response, whether a congenic background is required for use in syngeneic engraftment or adoptive cell transfer experiments and other factors.
HLA expression histogram for spleen cells in HLA-A11 mice on two genetic backgrounds
Figure 2: Histograms for HLA-A11 expression on spleen cells in representative animals, as measured using a pan-HLA-ABC antibody. Grey = wild type C57BL/6 control. Blue = three model #8907 hemizygous female mice (C57BL/6 background). Red = three model #9660 hemizygous female mice (CB6F1 background).
Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions for Taconic Models, Products and Services and the following terms of use:
Age in Weeks | Quantity 1 - 999 |
3 to 10 | $476.00 |
Age in Weeks | Quantity 1 - 999 |
3 to 10 | $476.00 |
Age in Weeks | Quantity 1 - 999 |
3 to 10 | €427,00 |
Age in Weeks | Quantity 1 - 999 |
3 to 10 | €427,00 |
Age in Weeks | Quantity 1 - 999 |
3 to 10 | $275.00 |
Age in Weeks | Quantity 1 - 999 |
3 to 10 | $275.00 |
Age in Weeks | Quantity 1 - 999 |
3 to 10 | €247,00 |
Age in Weeks | Quantity 1 - 999 |
3 to 10 | €247,00 |
Need help choosing the right Taconic Biosciences health standard for your research?
Use the Health Standard Selector to enter your exclusion list. The tool will tell you which health standards meet your requirements.
Speak with a PhD-level Field Application Scientist who can help you select the most appropriate model and maximize your experimental success.